TBResist is a Consortium of groups looking at the genome sequence data of MDR, XDR, and TDR TB strains has come together to carry out a joint analysis of their data in order to understand and find a way to counteract genomic drug resistance. The consortium will initially focus on strains that are well characterized clinically in terms of patient outcome (cure, treatment failure, death and when possible the presence or absence of co-HIV infection). The focus will begin on South Africa with the goal of expanding the scope to incorporate diverse geographies. The initial cohorts to work with have been identified as PROX, PYM One, PYM Two, CDC PETTS Study, and South Africa Medical Research Council.
The consortium will have the following main objectives:
1. Use collective data to define and understand the genomic foundations of TB drug resistance.
2. Use new found knowledge to develop a predictive analytics platform and service to support patient treatment
3. Provide molecular epidemiology information
4. Work toward the development of new diagnostics and vaccines
5. Aid in drug discovery